Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.20 EUR
−204.08 M EUR
154.27 M EUR
142.61 M
About Adaptive Biotechnologies Corporation
Sector
Industry
CEO
Chad Robins
Website
Headquarters
Seattle
Founded
2009
FIGI
BBG00PKDCX25
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 1HM is 4.99 EUR — it has decreased by −3.60% in the past 24 hours. Watch ADAPTIVE BIOTECHNOLOGIES CORPORATION stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ADAPTIVE BIOTECHNOLOGIES CORPORATION stocks are traded under the ticker 1HM.
1HM stock has fallen by −0.23% compared to the previous week, the month change is a 15.47% rise, over the last year ADAPTIVE BIOTECHNOLOGIES CORPORATION has showed a 24.43% increase.
We've gathered analysts' opinions on ADAPTIVE BIOTECHNOLOGIES CORPORATION future price: according to them, 1HM price has a max estimate of 9.47 EUR and a min estimate of 5.21 EUR. Watch 1HM chart and read a more detailed ADAPTIVE BIOTECHNOLOGIES CORPORATION stock forecast: see what analysts think of ADAPTIVE BIOTECHNOLOGIES CORPORATION and suggest that you do with its stocks.
1HM stock is 7.81% volatile and has beta coefficient of 1.77. Track ADAPTIVE BIOTECHNOLOGIES CORPORATION stock price on the chart and check out the list of the most volatile stocks — is ADAPTIVE BIOTECHNOLOGIES CORPORATION there?
Today ADAPTIVE BIOTECHNOLOGIES CORPORATION has the market capitalization of 782.07 M, it has increased by 4.16% over the last week.
Yes, you can track ADAPTIVE BIOTECHNOLOGIES CORPORATION financials in yearly and quarterly reports right on TradingView.
ADAPTIVE BIOTECHNOLOGIES CORPORATION is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
1HM earnings for the last quarter are −0.20 EUR per share, whereas the estimation was −0.26 EUR resulting in a 23.49% surprise. The estimated earnings for the next quarter are −0.24 EUR per share. See more details about ADAPTIVE BIOTECHNOLOGIES CORPORATION earnings.
ADAPTIVE BIOTECHNOLOGIES CORPORATION revenue for the last quarter amounts to 41.71 M EUR, despite the estimated figure of 36.14 M EUR. In the next quarter, revenue is expected to reach 43.83 M EUR.
1HM net income for the last quarter is −28.80 M EUR, while the quarter before that showed −43.15 M EUR of net income which accounts for 33.25% change. Track more ADAPTIVE BIOTECHNOLOGIES CORPORATION financial stats to get the full picture.
No, 1HM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 15, 2024, the company has 709.00 employees. See our rating of the largest employees — is ADAPTIVE BIOTECHNOLOGIES CORPORATION on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ADAPTIVE BIOTECHNOLOGIES CORPORATION EBITDA is −131.19 M EUR, and current EBITDA margin is −105.34%. See more stats in ADAPTIVE BIOTECHNOLOGIES CORPORATION financial statements.
Like other stocks, 1HM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ADAPTIVE BIOTECHNOLOGIES CORPORATION stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ADAPTIVE BIOTECHNOLOGIES CORPORATION technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ADAPTIVE BIOTECHNOLOGIES CORPORATION stock shows the neutral signal. See more of ADAPTIVE BIOTECHNOLOGIES CORPORATION technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.